Concentra price target raised to $25 from $24 at BofA

BofA raised the firm’s price target on Concentra (CON) to $25 from $24 and keeps a Buy rating on the shares after the company announced an agreement to acquire Nova Medical Centers for $265M, pre-announced Q4 results, and provided 2025 guide that was roughly in line with consensus excluding the Nova deal contribution. The firm raised its estimates for a better Q4 and the deal and raised its multiple given the increased visibility into estimates.